[PDF][PDF] Light chain–induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study
Journal of clinical oncology, 2010•researchgate.net
Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone
in Multiple Myeloma: Results o Page 1 Light Chain–Induced Acute Renal Failure Can Be
Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a
Phase II Study Heinz Ludwig, Zdenek Adam, Roman Hajek, Richard Greil, Elena Tóthová,
Felix Keil, Eva Maria Autzinger, Josef Thaler, Heinz Gisslinger, Alois Lang, Miklós Egyed, Irene
Womastek, and Niklas Zojer See accompanying articles on pages 4621 and 4630 From the …
in Multiple Myeloma: Results o Page 1 Light Chain–Induced Acute Renal Failure Can Be
Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a
Phase II Study Heinz Ludwig, Zdenek Adam, Roman Hajek, Richard Greil, Elena Tóthová,
Felix Keil, Eva Maria Autzinger, Josef Thaler, Heinz Gisslinger, Alois Lang, Miklós Egyed, Irene
Womastek, and Niklas Zojer See accompanying articles on pages 4621 and 4630 From the …
Purpose
To assess the efficacy of bortezomib-doxorubicin-dexamethasone (BDD) therapy in patients with multiple myeloma with light chain–induced acute renal failure.
researchgate.net